People of lower socioeconomic status face higher cancer death rates than their counterparts. African American men suffer the highest cancer incidence rate of any racial or ethnic group. But these gaps in cancer care can be addressed through policy. What does the case of Medicaid expansion reveal about cancer disparities in America? And what will … Continue reading The Atlantic: People v. Cancer
Think about the last time you were forced to make a decision in the face of uncertainty. You may have been choosing which job offer to accept or whether to move from renting to buying a home. You probably weighed the tradeoffs and asked yourself whether it made sense to gather additional information or to … Continue reading Do FDA alerts impact practice patterns?
The Flatiron study is proof of principle that real world evidence can be used to examine and inform health policy interventions, said Zafar, who led a discussion of Adamson’s study at the ASCO plenary session. Continue reading How to lead a research team from #hackathon to plenary in 6 months
Adamson spoke with Matthew Ong, a reporter with The Cancer Letter Before 2019, Blythe Adamson, a senior quantitative scientist at Flatiron Health, had never attended an annual meeting of the American Society of Clinical Oncology. In the shower, sometime in November 2018, Adamson came up with an idea for future research: “I think we should … Continue reading Q&A
This post has a summary of press coverage about results from a research study from Flatiron Health and Yale, following the Plenary Session presentation at ASCO 2019. We learned that Affordable Care Act (ACA) Medicaid expansion was associated with reduction in racial disparity in timely treatment of advanced cancer. Results were reported in the The … Continue reading Press: ACA Medicaid expansion eliminated racial disparities in timely cancer treatment
Our new study on the rise of immunotherapy drugs at the end of life with bladder cancer learned from real-world patients by using @flatironhealth curated EHR data. We hypothesized that advanced urothelial cancer patients would increasingly receive checkpoint inhibitors near the end of life, as they tend to have more favorable side effect profiles … Continue reading Immunotherapy increasing at end of life